Vascepa for Community-Acquired Pneumonia
(TIN-CAP Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you are on systemic anti-inflammatory therapy (like prednisone or methotrexate), you may not be eligible to participate.
How is the drug Icosapent Ethyl unique in treating community-acquired pneumonia?
Icosapent Ethyl, known for its use in reducing cardiovascular risk, is unique for community-acquired pneumonia as it may offer anti-inflammatory benefits, unlike standard treatments that primarily focus on antibiotics. This could provide a novel approach by potentially reducing inflammation in the lungs.12345
What is the purpose of this trial?
The goal of this clinical trial is to learn if icosapent ethyl (Vascepa) works to lessen the amount of inflammation in adults diagnosed with Community-Acquired Pneumonia (CAP). The main question it aims to answer is:What is the effect of taking Vascepa on inflammation in the arteries in patients with CAP? Researchers will compare the drug Vascepa to a placebo (a look-alike submstance that contains no drug) to see if Vascepa works to reduce inflammation in patients with CAP.Participants wil:* take Vacscepa or a placebo twice a day for 6 months* Visit the clinic 3 times (baseline, 30 days, and 6 months) for checkups and tests
Eligibility Criteria
This trial is for adults with Community-Acquired Pneumonia (CAP) who are interested in testing a treatment aimed at reducing artery inflammation. Specific eligibility details aren't provided, but typically participants must meet certain health criteria and not have conditions that could interfere with the study or their safety.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants take Vascepa or a placebo twice a day for 6 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Icosapent Ethyl
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ottawa Heart Institute Research Corporation
Lead Sponsor